A small nonfunctioning pancreatic NET: surveillance or surgery in Shanghai?
small nonfunctioning pancreatic NET surveillance surgery Shanghai
A small nonfunctioning pancreatic neuroendocrine tumour may be monitored or operated on; “small” and “nonfunctioning” do not settle the choice. Shanghai pancreatic specialists can compare pathology grade, growth and location with the burdens of each path. eastmedgo can assemble the scans and reports so the second opinion addresses the real disagreement.
By eastmedgo editorial ·
On this page
Make sure this is the right diagnostic category
This discussion concerns a small, apparently localized, nonfunctioning pancreatic neuroendocrine tumor, often shortened to pNET. Nonfunctioning means it does not cause a clinical hormone-excess syndrome; it does not mean harmless or incapable of spreading. A well-differentiated NET is also different from a poorly differentiated neuroendocrine carcinoma and from the much more common pancreatic ductal adenocarcinoma. Those diagnoses should not share a surveillance recommendation simply because they occur in the pancreas. Ask whether the diagnosis is suspected from imaging or supported by tissue, and whether symptoms or family history suggest a functioning tumor or inherited syndrome.
Grade adds information that diameter cannot provide
When tissue is available, the pathology report should describe differentiation and grade, including the Ki-67 proliferation measure and other relevant findings. These help estimate biological behavior, but a small biopsy samples only part of the lesion. A low value should be interpreted with imaging and the clinical course rather than treated as a guarantee. The team may discuss endoscopic ultrasound and sampling when the result could change management; biopsy is not automatically required in every tiny lesion considered for observation. Ask what uncertainty remains if sampling is deferred and what new finding would lead to reconsideration.
Sources and references: [2] [3] [4]
Review growth, duct changes and the extent of disease
Compare original scans over time using a consistent imaging approach where possible. The review should describe the lesion's position in the pancreatic head, body or tail, its relation to the main pancreatic duct and vessels, and any concerning lymph nodes or distant findings. New duct dilation or convincing growth can matter even when the overall diameter still sounds small. Additional functional imaging may help selected assessments but does not replace anatomical imaging. Ask what each proposed test is intended to resolve, rather than collecting every available scan before the specialist has reviewed the existing files.
Observation must be an active, documented strategy
International expert guidance supports observation for selected small, asymptomatic tumors and individualized decisions in the roughly 1–2 cm range. These are conditional recommendations, not a promise that all lesions below a size threshold are safe to leave alone. Grade, growth, duct findings, age, other illnesses, preferences and access to follow-up alter the balance. A surveillance plan should specify the imaging method, first reassessment, who compares the scans and the triggers for discussing treatment. Ask how missed appointments or living far from the reviewing center would be handled. Surveillance without a responsible clinician and review schedule is not the same strategy.
The operation's burden depends on where the tumor sits
Some selected lesions may allow a tissue-sparing operation, while others require a larger pancreatic resection. Tumors in the head and tail can therefore lead to very different procedures despite similar size. Discuss whether lymph node assessment is needed and whether preserving pancreas compromises an adequate oncological operation. Risks include pancreatic leakage, bleeding, infection and later problems with digestion or blood sugar, with their likelihood depending on the procedure and patient. Ask the surgeon to name the proposed operation and explain why its expected benefit outweighs both surgical harm and the risk of continued observation in your case.
What the Shanghai resource can add to this decision
A small nonfunctioning pancreatic neuroendocrine tumour does not always call for immediate surgery, but surveillance also needs sound grading and an imaging plan. Fudan University Shanghai Cancer Center has disease-specific work on tumour biology and surgical risk. A Shanghai review can bring pancreatic surgery, pathology and imaging together to compare location, Ki-67, growth, the burden of monitoring and the cost of an operation, with a clear point to reconsider the choice. Start with our Pancreatic neuroendocrine tumor guide, then bring your main question to eastmedgo.
Prepare the evidence for both possible choices
Send all dated CT or MRI files, endoscopic ultrasound reports, pathology and Ki-67 results if obtained, and details of any specialized imaging. Record symptoms, weight changes, diabetes or digestive problems, medicines, other major illnesses and relevant family history. Include the previous recommendation and its reasoning so the second opinion can address the actual disagreement. If surveillance is proposed, request a written alternative describing what would lead to surgery; if surgery is proposed, ask why observation is less suitable. eastmedgo can organise the records needed for comparing surveillance and surgery using Ki-67, growth and pancreatic location, match you with Shanghai specialists and coordinate bilingual communication and return-home handover.
Plan costs and local follow-up whichever route is chosen
For surveillance, consider repeated imaging, consultations and travel over time, not just the first review. For surgery, request separate estimates for assessment, anesthesia, the operation, admission, complication care and subsequent nutritional or diabetes support. Confirm where follow-up can occur and who will review changes promptly; removing a tumor does not automatically eliminate future monitoring. Seek local assessment for new jaundice, persistent vomiting or significant deterioration, and urgent care for severe symptoms rather than waiting for an overseas appointment. Base the budget and travel plan on the surveillance or operation actually recommended, with room for reassessment. To discuss your records and the next step, contact eastmedgo.
Common questions
Does nonfunctioning mean the tumor is benign?
No. It describes the absence of a clinical hormone-excess syndrome, not the absence of malignant potential. The diagnosis, grade, disease extent and course over time still matter when choosing observation or treatment.
Is a tumor under 2 cm always suitable for surveillance?
No. Size is one factor. Symptoms, growth, duct dilation, grade, suspected spread, surgical burden and reliable access to monitoring can change the recommendation. Ask for an individualized explanation rather than treating a threshold as a universal rule.
If observation is reasonable now, can surgery still be discussed later?
Yes. Structured surveillance includes reassessment and criteria for changing course. Growth or another concerning development may prompt surgery or additional evaluation. That possibility should be planned from the start; observation is not a promise that treatment will never be needed. At the start of surveillance, agree when the next scan will be reviewed and which changes would trigger another surgical discussion.
Sources and references
- NCI — Pancreatic neuroendocrine tumors, patient PDQ
- NANETS — Surgical management of pancreatic neuroendocrine tumors, 2020
- ENETS — Nonfunctioning pancreatic neuroendocrine tumours guidance, 2023
- Mayo Clinic — Pancreatic neuroendocrine tumors: diagnosis and treatment
- Fudan University — Nonfunctioning pancreatic NET research, 2025
- Fudan University Shanghai Cancer Center — Pancreas and hepatobiliary multidisciplinary team